Zymeworks (ZYME) Competitors $13.33 -0.68 (-4.85%) Closing price 04:00 PM EasternExtended Trading$13.28 -0.05 (-0.38%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. SRRK, ACAD, VKTX, SWTX, PTGX, MLTX, IMVT, AAPG, CRNX, and KYMRShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), Ascentage Pharma Group International (AAPG), Crinetics Pharmaceuticals (CRNX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors Scholar Rock ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Protagonist Therapeutics MoonLake Immunotherapeutics Immunovant Ascentage Pharma Group International Crinetics Pharmaceuticals Kymera Therapeutics Zymeworks (NYSE:ZYME) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Is ZYME or SRRK more profitable? Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% Scholar Rock N/A -118.22%-82.01% Which has higher valuation & earnings, ZYME or SRRK? Zymeworks has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$93.38M9.95-$118.67M-$1.49-8.95Scholar Rock$33.19M111.43-$246.29M-$2.53-15.40 Do analysts recommend ZYME or SRRK? Zymeworks currently has a consensus price target of $21.00, suggesting a potential upside of 57.54%. Scholar Rock has a consensus price target of $42.67, suggesting a potential upside of 9.54%. Given Zymeworks' higher probable upside, equities analysts clearly believe Zymeworks is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media prefer ZYME or SRRK? In the previous week, Scholar Rock had 10 more articles in the media than Zymeworks. MarketBeat recorded 11 mentions for Scholar Rock and 1 mentions for Zymeworks. Scholar Rock's average media sentiment score of 0.92 beat Zymeworks' score of 0.33 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ZYME or SRRK? Zymeworks has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ZYME or SRRK? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryZymeworks beats Scholar Rock on 9 of the 15 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$928.87M$776.90M$5.70B$21.12BDividend YieldN/A4.84%4.69%3.60%P/E Ratio-8.891.4028.0728.44Price / Sales9.9525.35449.2060.36Price / CashN/A19.5636.2222.92Price / Book2.016.798.664.69Net Income-$118.67M-$4.32M$3.25B$995.51M7 Day Performance-6.46%1.33%4.20%1.64%1 Month Performance4.88%3.74%10.82%5.92%1 Year Performance25.40%8.18%34.70%11.50% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks2.8989 of 5 stars$13.33-4.9%$21.00+57.5%+34.7%$928.87M$93.38M-8.89460Upcoming EarningsSRRKScholar Rock3.2631 of 5 stars$38.59+3.1%$42.67+10.6%+342.4%$3.66B$33.19M-15.25140ACADACADIA Pharmaceuticals4.2594 of 5 stars$21.89+4.3%$27.88+27.3%+24.7%$3.66B$957.80M15.98510Positive NewsAnalyst ForecastVKTXViking Therapeutics4.8493 of 5 stars$31.63+1.7%$87.15+175.5%-33.5%$3.55BN/A-27.5020Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSWTXSpringWorks Therapeutics1.3425 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230PTGXProtagonist Therapeutics1.3781 of 5 stars$55.23+4.2%$66.10+19.7%+28.3%$3.42B$434.43M73.64120News CoverageInsider TradeMLTXMoonLake Immunotherapeutics2.1674 of 5 stars$50.86+3.8%$74.50+46.5%+20.7%$3.26BN/A-22.112News CoveragePositive NewsOptions VolumeIMVTImmunovant1.6052 of 5 stars$18.59+2.5%$36.30+95.3%-34.4%$3.18BN/A-6.78120News CoveragePositive NewsGap DownAAPGAscentage Pharma Group InternationalN/A$36.20-5.3%N/AN/A$3.15B$134.35M0.00600Lockup ExpirationGap DownCRNXCrinetics Pharmaceuticals3.6692 of 5 stars$33.02+3.4%$69.50+110.5%-43.1%$3.09B$1.04M-8.64210Positive NewsKYMRKymera Therapeutics3.0325 of 5 stars$44.90+0.9%$59.11+31.7%+6.9%$2.92B$47.07M-14.48170Positive News Related Companies and Tools Related Companies SRRK Alternatives ACAD Alternatives VKTX Alternatives SWTX Alternatives PTGX Alternatives MLTX Alternatives IMVT Alternatives AAPG Alternatives CRNX Alternatives KYMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
